Gastrointestinal Microbiome Study of Appendiceal Cancer

Description

This study analyzes the gastrointestinal microbiome of appendiceal cancer patients with peritoneal spread scheduled to undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Participants will provide fecal samples pre- and post-operatively.

Conditions

Pseudomyxoma Peritonei, Appendiceal Neoplasm, Cancer, Appendiceal

Study Overview

Study Details

Study overview

This study analyzes the gastrointestinal microbiome of appendiceal cancer patients with peritoneal spread scheduled to undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Participants will provide fecal samples pre- and post-operatively.

A Cohort Study of the Gastrointestinal Microbiome in Appendiceal Cancer With Peritoneal Spread

Gastrointestinal Microbiome Study of Appendiceal Cancer

Condition
Pseudomyxoma Peritonei
Intervention / Treatment

-

Contacts and Locations

Baltimore

Mercy Medical Center, Baltimore, Maryland, United States, 21202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of appendiceal cancer with peritoneal spread
  • * Candidate for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
  • * ≥18 and ≤ 80 years of age
  • * Eastern Cooperative Oncology Group performance status score of ≤2/Karnofsky performance status (KPS) ≥70%
  • * Signed Institutional Review Board approved informed consent
  • * \<18 years of age
  • * Pregnant women
  • * Concurrent severe medical problems unrelated to malignancy

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mercy Medical Center,

Armando Sardi, MD, PRINCIPAL_INVESTIGATOR, Mercy Medical Center

Study Record Dates

2024-12